186
Acknowledgments
This work was supported by the Hellenic Foundation for Research
and Innovation (H.F.R.I.) under the “First Call for
H.F.R.I. Research Projects to support Faculty members and
Researchers and the procurement of high-cost research equipment
grant” (Project Number:991, acronym PROTECT to AGT). We
would like to acknowledge Evgenios K. Stylos for his suggested
comments and corrections to this chapter.
References
1. Mitra AK et al (2015) Novel delivery
approaches for cancer therapeutics. J Control
Release 219:248–268
2. Tibbitt MW, Dahlman JE, Langer R (2016)
Emerging frontiers in drug delivery. J Am
Chem Soc 138(3):704–717
3. Farokhzad OC, Langer R (2009) Impact of
nanotechnology on drug delivery. ACS Nano
3(1):16–20
4. Ghosh I, Nau WM (2012) The strategic use
of supramolecular pK(a) shifts to enhance the
bioavailability of drugs. Adv Drug Deliv Rev
64(9):764–783
5. Ma X, Zhao Y (2015) Biomedical applications
of supramolecular systems based on host–guest
interactions. Chem Rev 115(15):7794–7839
6. Yousaf A et al (2015) Applications of calixarenes in cancer chemotherapy: facts and perspectives. Drug Des Devel Ther 9:2831–2838
7. Mo J et al (2016) Paclitaxel-loaded phosphonated calixarene nanovesicles as a modular
drug delivery platform. Sci Rep 6:23489
8. Renziehausen A et al (2019) Encapsulation
of temozolomide in a calixarene nanocapsule
improves its stability and enhances its therapeutic efficacy against glioblastoma. Mol Cancer
Ther 18:1497–1505
9. Stupp R et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352(10):987–996
10. Linz U (2010) Commentary on effects of
radiotherapy with concomitant and adjuvant
temozolomide versus radiotherapy alone on
survival in glioblastoma in a randomised phase
III study: 5-year analysis of the EORTCNCIC trial (Lancet Oncol. 2009;10:459-466).
Cancer 116(8):1844–1846
11. Meer L et al (1986) In vivo metabolism and
reaction with DNA of the cytostatic agent,
5-(3,3-dimethyl-1-triazeno)imidazole-4carboxamide (DTIC). Biochem Pharmacol
35(19):3243–3247
12. Ostermann S et al (2004) Plasma and cerebrospinal fluid population pharmacokinetics of
temozolomide in malignant glioma patients.
Clin Cancer Res 10(11):3728–3736
13. Coleman AW et al (2008) Toxicity and biodistribution of para-sulfonato-calix[4]arene in
mice. New J Chem 32(5):780–782
14. Da Silva E, Shahgaldian P, Coleman AW
(2004) Haemolytic properties of some watersoluble para-sulphonato-calix-[n]-arenes. Int J
Pharm 273(1–2):57–62
15. Verbeeck RK, Musuamba FT (2012) The
revised EMA guideline for the investigation of
bioequivalence for immediate release oral formulations with systemic action. J Pharm Pharm
Sci 15(3):376–388
16. El Mubarak MA et al (2019) Development
and validation of simple step protein precipitation UHPLC-MS/MS methods for quantitation of temozolomide in cancer patient
plasma samples. J Pharm Biomed Anal
162:164–170
Antonis D. Tsiailanis et al.
Acknowledgments
This work was supported by the Hellenic Foundation for Research
and Innovation (H.F.R.I.) under the “First Call for
H.F.R.I. Research Projects to support Faculty members and
Researchers and the procurement of high-cost research equipment
grant” (Project Number:991, acronym PROTECT to AGT). We
would like to acknowledge Evgenios K. Stylos for his suggested
comments and corrections to this chapter.
References
1. Mitra AK et al (2015) Novel delivery
approaches for cancer therapeutics. J Control
Release 219:248–268
2. Tibbitt MW, Dahlman JE, Langer R (2016)
Emerging frontiers in drug delivery. J Am
Chem Soc 138(3):704–717
3. Farokhzad OC, Langer R (2009) Impact of
nanotechnology on drug delivery. ACS Nano
3(1):16–20
4. Ghosh I, Nau WM (2012) The strategic use
of supramolecular pK(a) shifts to enhance the
bioavailability of drugs. Adv Drug Deliv Rev
64(9):764–783
5. Ma X, Zhao Y (2015) Biomedical applications
of supramolecular systems based on host–guest
interactions. Chem Rev 115(15):7794–7839
6. Yousaf A et al (2015) Applications of calixarenes in cancer chemotherapy: facts and perspectives. Drug Des Devel Ther 9:2831–2838
7. Mo J et al (2016) Paclitaxel-loaded phosphonated calixarene nanovesicles as a modular
drug delivery platform. Sci Rep 6:23489
8. Renziehausen A et al (2019) Encapsulation
of temozolomide in a calixarene nanocapsule
improves its stability and enhances its therapeutic efficacy against glioblastoma. Mol Cancer
Ther 18:1497–1505
9. Stupp R et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352(10):987–996
10. Linz U (2010) Commentary on effects of
radiotherapy with concomitant and adjuvant
temozolomide versus radiotherapy alone on
survival in glioblastoma in a randomised phase
III study: 5-year analysis of the EORTCNCIC trial (Lancet Oncol. 2009;10:459-466).
Cancer 116(8):1844–1846
11. Meer L et al (1986) In vivo metabolism and
reaction with DNA of the cytostatic agent,
5-(3,3-dimethyl-1-triazeno)imidazole-4carboxamide (DTIC). Biochem Pharmacol
35(19):3243–3247
12. Ostermann S et al (2004) Plasma and cerebrospinal fluid population pharmacokinetics of
temozolomide in malignant glioma patients.
Clin Cancer Res 10(11):3728–3736
13. Coleman AW et al (2008) Toxicity and biodistribution of para-sulfonato-calix[4]arene in
mice. New J Chem 32(5):780–782
14. Da Silva E, Shahgaldian P, Coleman AW
(2004) Haemolytic properties of some watersoluble para-sulphonato-calix-[n]-arenes. Int J
Pharm 273(1–2):57–62
15. Verbeeck RK, Musuamba FT (2012) The
revised EMA guideline for the investigation of
bioequivalence for immediate release oral formulations with systemic action. J Pharm Pharm
Sci 15(3):376–388
16. El Mubarak MA et al (2019) Development
and validation of simple step protein precipitation UHPLC-MS/MS methods for quantitation of temozolomide in cancer patient
plasma samples. J Pharm Biomed Anal
162:164–170
Antonis D. Tsiailanis et al.